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rare inherited intestinal disorders characterized by intractable,
sometimes life-threatening, diarrhea and nutrient malab-
sorption; some have been associated with mutations in
diacylglycerol-acyltransferase 1 (DGAT1), which catalyzesDownloaded for Anonymous User (n/a) at ULAKBIM Academic  Bask
For personal use only. No other uses without permissionformation of triacylglycerol from diacylglycerol and acyl-CoA.
We investigated the mechanisms by which DGAT1 deficiency
contributes to intestinal failure using patient-derived organo-
ids. METHODS: We collected blood samples from 10 patients,
from 6 unrelated pedigrees, who presented with early-onsetent Universitesi from ClinicalKey.com by Elsevier on May 06, 2019.
. Copyright ©2019. Elsevier Inc. All rights reserved.
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
Mutations in DGAT1 have recently been identified in
patients with congenital diarrheal disorders (CDDs), but
the underlying molecular pathomechanisms have
remained largely elusive.
NEW FINDINGS
The authors identified 10 patients with DGAT1 deficiency
representing the largest cohort to date, linking gut
epithelial lipid metabolism and lipotoxicity to CDD; and
rescued aberrant lipid metabolism with isoenzyme DGAT2.
LIMITATIONS
Although the authors show exogenous DGAT1 or DGAT2
expression or proteasome inhibitors may overcome
defects, future studies may need to address how that
knowledge can be translated to targeted therapies.
IMPACT
The authors highlight the importance of identifying the
genetic defect in patients with CDD, and showcase
further use of gut organoid technology to study rare
diseases of the gastrointestinal tract.
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(fatal) protein-losing enteropathy with intestinal failure; we
performed next-generation sequencing analysis of DNA from 8
patients. Organoids were generated from duodenal biopsies
from 3 patients and 3 healthy individuals (controls). Caco-2
cells and patient-derived dermal fibroblasts were transfected
or transduced with vectors that express full-length or mutant
forms of DGAT1 or full-length DGAT2. We performed CRISPR/
Cas9-guided disruption of DGAT1 in control intestinal organo-
ids. Cells and organoids were analyzed by immunoblot,
immunofluorescence, flow cytometry, chromatography, quan-
titative real-time polymerase chain reaction, and for the activity
of caspases 3 and 7. RESULTS: In the 10 patients, we identified
5 bi-allelic loss-of-function mutations in DGAT1. In patient-
derived fibroblasts and organoids, the mutations reduced
expression of DGAT1 protein and altered triacylglycerol meta-
bolism, resulting in decreased lipid droplet formation after
oleic acid addition. Expression of full-length DGAT2 in patient-
derived fibroblasts restored formation of lipid droplets. Orga-
noids derived from patients with DGAT1 mutations were more
susceptible to lipid-induced cell death than control organoids.
CONCLUSIONS: We identified a large cohort of patients with
congenital diarrheal disorders with mutations in DGAT1 that
reduced expression of its product; dermal fibroblasts and in-
testinal organoids derived from these patients had altered lipid
metabolism and were susceptible to lipid-induced cell death.
Expression of full-length wildtype DGAT1 or DGAT2 restored
normal lipid metabolism in these cells. These findings indicate
the importance of DGAT1 in fat metabolism and lipotoxicity in
the intestinal epithelium. A fat-free diet might serve as the first
line of therapy for patients with reduced DGAT1 expression. It
is important to identify genetic variants associated with
congenital diarrheal disorders for proper diagnosis and selec-
tion of treatment strategies.TRKeywords: CDD; Genomic; PLE; 3-D Culture Model.
ongenital diarrheal disorders (CDDs) are a group of*Authors share co-first authorship; § Authors share co-senior authorship.
Abbreviations used in this paper: B-LCL, B lymphoblastoid cell line; BSA,
bovine serum albumin; CDD, congenital diarrheal disorder; cDNA, com-
plementary DNA; DG, diacylglycerol; DGAT1, diacylglycerol-acyltransfer-
ase 1; hSI-EM, human small intestine expansion medium; FFA, free fatty
acid; GI, gastrointestinal; OA, oleic acid; PB, PiggyBac transposon; PBS,
phosphate-buffered saline; PLE, protein-losing enteropathy; sgRNA, sin-
gle-guide RNA; SSC, Side Scatter; TG, triacylglycerol; WT, wild-type.
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access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
0016-5085
https://doi.org/10.1053/j.gastro.2018.03.040Crare inherited intestinal disorders that are charac-
terized by intractable, sometimes life-threatening, diarrhea
and nutrient malabsorption. CDDs can be classified based on
their aberrations in absorption and transport of nutrients
and electrolytes, enterocyte differentiation and polarization,
enteroendocrine cell differentiation, or dysregulation of the
intestinal immune response.1 Congenital protein-losing en-
teropathy (PLE) is a type of CDD that is characterized by
increased protein loss from the gastrointestinal (GI) system.
Patients with PLE often suffer from hypoproteinemia, fat
malabsorption, fat-soluble vitamin deficiencies, and malnu-
trition. Recently, we have identified germline loss-of-
function mutations in CD55 as a major monogenic etiology
for congenital PLE.2
Previously, mutations in the gene encoding diacylglycerol-
acyltransferase 1 (DGAT1) were found to underlie a syn-
drome of diarrhea and congenital PLE.3–6 DGAT1 and its
isozyme DGAT2 (encoding for diacylglycerol-acyltransferase
2) are responsible for the conversion of diacylglycerol (DG)
and fatty acyl-CoA to triacylglycerol (TG) in humans.7,8 TG
is themain energy substrate stored in human adipose tissue, isDownloaded for Anonymous User (n/a) at ULAKBIM Academic  Bask
For personal use only. No other uses without permissionessential for milk production in the mammary gland, and is
part of the very low-density lipoprotein–mediated transport of
lipids to peripheral tissue.9,10 In the human small intestine,
DGAT1 is the only highly expressed enzyme,whereasDGAT2 is
mainly expressed in the liver.3,11 In enterocytes, TG is stored in
lipid droplets or packaged into chylomicrons before transport
into the lymphatic system.8,12,13
The pathomechanism responsible for intestinal failure
and PLE in DGAT1 deficiency has remained unclear.
Through next-generation sequencing, we identified 10
additional patients from 6 unrelated pedigrees with 5
different, novel bi-allelic mutations in DGAT1 leading to
severe, sometimes fatal course of PLE and fat intolerance.
We took this unique opportunity to further shed light on the
fundamental pathomechanisms of human DGAT1 deficiency.
Materials and Methods
Study Approval
The study was approved by the responsible local ethics
committees (Ethics Commission of the Medical University ofent Universitesi from ClinicalKey.com by Elsevier on May 06, 2019.
. Copyright ©2019. Elsevier Inc. All rights reserved.
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ical Center Utrecht). All participants provided written informed
consent for the collection of samples and subsequent analysis.
DNA Sequencing
Whole-exome sequencing was performed on patients as
previously described.14,15 Targeted panel sequencing was
performed as previously described.16 Conventional Sanger
sequencing was performed for validation and segregation
analysis of variants.
Cell Culture
Organoids were generated from duodenal biopsies that
were obtained from 3 healthy controls and 3 patients during
duodenoscopy for diagnostic purposes, as described in detail in
the Supplementary Materials and Methods. The healthy con-
trols were patients suspected of celiac disease or inflammatory
bowel disease, who did not show abnormalities on endoscopic
and histological examinations.
Caco-2 cells and patient-derived fibroblasts were cultured
in Dulbecco’s modified Eagle’s medium with/without GlutaMax
and high glucose (Life Technologies, Carlsbad, CA) supple-
mented with 10% heat-inactivated fetal bovine serum (GE
Health Care, Little Chalfont, UK), 100 U/mL penicillin (Gibco,
Waltham, MA), 100 mg/mL streptomycin (Gibco), and 1 mM
sodiumpyruvate (Gibco) at 37C and 5% CO2. Patient-derived
Epstein-Barr virus B lymphoblastoid cell line (B-LCL) was
maintained in RPMI 1640 with 10% heat-inactivated fetal
bovine serum, 100 U/mL penicillin (Gibco), and 100 mg/mL
streptomycin (Gibco).
CRISPR/Cas9 Knockout of DGAT1
Plasmid constructs for the expression of DGAT1 single-
guide RNAs (sgRNA) and Cas9 nuclease were generated
as previously described and outlined in Supplementary Mate-
rial and Methods.17 Three DGAT1 sgRNAs targeting exon 7 and
1 sgRNA targeting intron 6-7 were designed. Two different
sgRNA (mix)-plasmids were used for transfection: sgRNA#2
and a mix of sgRNA#6, sgRNA#7, and sgRNA#8 (sgRNA#678).
Hygromycin-resistance was achieved by co-transfection with
the PiggyBac (PB) Transposon System (plasmids PB-
Hygromycin and PB-Transposase were kindly provided by
Bon-Kyoung Koo).
Transfection of healthy intestinal organoids was performed
by electroporation, as described previously18 and extensively in
Supplementary Materials and Methods.
Lipid Droplet Assays
Oleic acid (OA) was conjugated to bovine serum albumin
(BSA) as described in Supplementary Materials and Methods.
Organoids were grown in expansion medium (EM) on black
clear-bottom 96-well imaging plates (Corning Life Sciences,
Corning, NY). On day 6, the organoids were incubated with 1
mM OA/BSA for 17 hours in presence or absence of 0.1 mM
DGAT1 inhibitor (AZD 3988; Tocris, Bristol, UK). Organoids
were then fixed in 4% formaldehyde for 30 minutes at room
temperature. Cells were washed in phosphate-buffered saline
(PBS) and stained with 0.025 mg/mL LD54019 and 40,
6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich, St Louis,Downloaded for Anonymous User (n/a) at ULAKBIM Academic  Bask
For personal use only. No other uses without permissionMO) in PBS for 15 minutes at room temperature in the dark.
Cells were washed and stored in PBS. Imaging of the organoids
was performed using a Leica (Wetzlar, Germany) SP8X laser-
scanning confocal microscope outfitted with a white light
laser. The acquired stacks were processed and analyzed with
Fiji/ImageJ (National Institutes of Health, Bethesda, MD)20,21;
shown are maximum projections of approximately 15-mm
stacks.
For flow cytometry analysis, organoids were grown and
treated with OA/BSA in the same manner as for the confocal
analysis. After overnight incubation with 1 mM OA/BSA, the
cells were harvested by pipetting and dissociated using TrypLE
Express (ThermoFisher, Waltham, MA) until single cells were
acquired. The cells were then fixed and stained in the same
manner as for the confocal analysis and assayed using a BD
FACS Canto II (BD Biosciences, San Jose, CA).
Fibroblasts were seeded at 6  104 cells in a 6-well plate
and allowed to adhere overnight. Cells were then treated with
OA positive control from the Lipid Droplet Fluorescence Assay
(#500001; Cayman Chemical, Ann Arbor, MI) at 1:4000 dilution
for 24 hours. Cells were fixed and stained according to the
manufacturer’s protocol and assayed using BD FACS Fortessa
(BD Biosciences, Franklin Lakes, NJ).
Cloning and Retrovirus Production
DGAT1 (ENST00000528718.5) and DGAT2
(ENST00000228027.11) complementary DNAs (cDNAs) were
amplified by polymerase chain reaction from HEK293 cDNA
library and cloned into pDONR221 using BP reaction according
to the manufacturer’s protocol (Thermo Fisher). LR reaction
was performed into pFMIG for wild-type (WT) DGAT1 and
DGAT2 with N-terminal Streptavidin-HA tag.
Quantitative Real-Time Polymerase
Chain Reaction
RNA was isolated from Caco-2 cells or organoids grown in
either EM or differentiation medium (DM) for 5 days, used to
synthesize cDNA by using the iScript cDNA synthesis kit (Bio-
Rad, Hercules, CA) and amplified with SYBR green supermix
(BIO-Rad) in a Light Cycler96 (BIO-Rad) according to the
manufacturer’s protocol. Details on analysis and primers are
given in Supplementary Materials and Methods.
Western Blotting
Cell lysates were generated and Western blotting was
performed as described in the Supplementary Materials and
Methods.
Thin Layer Chromatography
Organoids were grown in EM for 7 days and then prepared
for Folch extraction as described previously22 and in the
Supplementary Materials and Methods. Thin layer chromatog-
raphy was performed by spotting the isolated lipid phase on
aluminium-backed silica plates (Merck Millipore, Burlington,
MA). As reference samples 1,3-dipentadecanoin (DG, C15:0/-/
C15:0), tripentadecanoin (TG, C15:0/C15:0/C15:0) and
triheptadecanoin (TG, C17:0/C17:0/C17:0) were included. The
plates were then developed in a mobile phase of hex-
ane:diethylether:acetic acid (60:15:2). The lipid bands wereent Universitesi from ClinicalKey.com by Elsevier on May 06, 2019.
. Copyright ©2019. Elsevier Inc. All rights reserved.
July 2018 DGAT1 Deficiency Impairs Lipid Metabolism 133visualized by spraying the plates with a solution of 10% CuSO4
(wt/vol) in 10% H2SO4 (vol/vol) and subsequently heating the
plates to 120C for 30 minutes, as described previously23 to
calculate DG/TG ratios, band intensities were quantified by
Fiji/ImageJ.20,21Lipotoxicity Assays
For the propidium iodide staining, organoids were grown
and incubated with varying concentrations of OA as described
for the lipid droplet confocal assay. The organoids were then
washed with Hank’s balanced salt solution (HBSS) (Gibco),
and stained with Hoechst 1 mg/mL (Sigma-Aldrich) and pro-
pidium iodide 0.1 mg/mL (ThermoFisher) in HBSS at room
temperature for 15 minutes. Organoids were imaged by an
inverted Olympus IX53 epifluorescence microscope (Tokyo,
Japan).
For the Caspase-Glo 3/7 assay (Promega, Madison, WI),
organoids were grown on TC-treated 96-well plates (Greiner,
Kremsmunster, Austria) and incubated with OA as was done for
the propidium iodide staining. Organoids were washed and
resuspended in HBSS and transferred to a white-walled 96-well
plate (Greiner). The assay was performed according to theFigure 1. Pedigrees, mutations, and genetic location of 6 families
deficiency and chromatograms showing mutation in affected p
are heterozygous for mutation indicated, and empty shapes in
identified in this study in black and previously identified mutation
Downloaded for Anonymous User (n/a) at ULAKBIM Academic  Bask
For personal use only. No other uses without permissionmanufacturer’s protocol and luminescence was measured on a
Tristar 2 luminometer (Berthold Technologies, Oak Ridge, TN).Statistical Analysis
Data are presented as mean ± SD. Experiments were per-
formed with a minimum of 3 replications. Statistical signifi-
cance was determined at P  .05 using 2-way analysis of
variance with Tukey’s multiple comparison test, a Mann-
Whitney U test, or a Student t test where appropriate. Signifi-
cance is indicated as P  .05 (*), P  .01 (**), or P  .001 (***)
or P < .0001 (****).Results
Clinical Phenotype
We investigated 10 patients from 5 consanguineous
families and 1 family of unknown consaguinity with unaf-
fected parents. All of the patients had a history of intestinal
failure due to congenital diarrhea and/or vomiting, resulting
in failure to thrive. (Figure 1A, Table 1, Supplementary
Table 1, see Supplementary Materials and Methods forwith DGAT1 deficiency. (A) Pedigrees of families with DGAT1
atients. Filled shapes indicate affected individuals, half-filled
dicate WT. (B) Exonic scheme of DGAT1 showing mutations
s in red.3–6
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Table 1.Patient Characteristics
Patient ID P1 P2 P3 P4 P5 P6 P7 P8 P9 P10
Demographics
Current age and gender 4.5 y, M Deceased, F 2 y, F 8 y, M 2 y, M 6 y, M 14 y, M 17 y, M 10 y, F 10 y, F
Country of origin
and ethnicity
Turkey, Turkish Turkey,
Turkish
Turkey, Turkish Turkey, Turkish Turkey,
Turkish
Turkey, Turkish The Netherlands,
Caucasian
The Netherlands,
Caucasian
The Netherlands,
Caucasian
The Netherlands,
Caucasian
Age of clinical onset Birth Birth 3 wk 2 mo 40 d 2.5 mo First month First month Birth Birth
Disease manifestations
Failure to thrive Yes Yes Yes Yes Yes Yes No Yes Yes Yes
Vomiting Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Diarrhea Yes, fatty Yes Yes Yes Yes, bloody
and watery
Yes, watery No No Yes Yes
Hypoalbuminemia Yes Yes Yes Yes Yes Yes No No Yes Yes
Hypogammaglobulinemia Yes Yes Yes Yes Yes Yes ND ND Yes Yes
Edema Yes Yes Yes No No No No No No No
GI examinations
(endoscopy
and imaging)
Normal Normal Normal Normal ND Normal Normal Normal Normal Normal
Hematoxylin-eosin
and electron
microscopy
Normal Normal Duodenal enterocytic
lipid accumulation,
microvilli are
shortened and
rarefied
Normal ND Focal
vacuolization
at one area
and partially
blunted villi
Normal
histology
(on fat-free
diet)
Normal histology
(on fat-free
diet)
Misdiagnosis
of atypical
MVID based
on CD10
positive
globules on
LM and
laterally
located
microvilli
on EM
Misdiagnosis of
atypical
MVID based
on CD10
positive
globules on
LM and
laterally
located
microvilli
on EM
Extra-GI manifestations Recurrent infections,
otitis media
Recurrent
infections
Corneal cystine crystal
accumulation and
intermittent
metabolic acidosis
ND Hepatomegaly
and jaundice
Recurrent
infections
Gilles de la
Tourette
syndrome
Gilles de la
Tourette
syndrome
Recurrent
infections
Recurrent
infections
Clinical course
Treatments Fat-free formula and
MCT, albumin
infusions
Albumin
infusions
Albumin, TPN Cholestyramine Creon pancreatic
lipase, hydrolyzed
formula
Creon
pancreatic
lipase
Monthly infusion
of Intralipid
and Omegaven
suppletion of
lipid-soluble
vitamins
Monthly infusion
of Intralipid and
Omegaven
suppletion
of lipid-soluble
vitamins
TPN and small
bowel
transplantation
TPN, recently
started with
fat-free
formula
Outcome Asymptomatic
and normal
growth with
low-fat
diet þ MCT oil þ
fat-free formula
Patient
passed
away at
6 mo due
to sepsis
Stool frequency once
a day with Basic
F formula feeding
Reduced stool
volume and
frequency on
cholestyramine
treatment
Stool frequency
reduced on Creon
treatment; weight
and height are
still below
3rd percentile
Stool frequency
reduced on
Creon treatment;
after 2 y,
symptoms
resolved
spontaneously
Enteral feeding
without fat
Enteral feeding
without fat
Tolerates
enteral
feeding,
but still
stunted
Tolerates enteral
feeding,
but still
stunted
EM, electron microscopy; F, female; GI, gastrointestinal; LM, light microscopy; M, male; MCT, medium-chain triglyceride; MVID, microvillus inclusion disease; ND, not
determined; TPN, total parenteral nutrition.
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July 2018 DGAT1 Deficiency Impairs Lipid Metabolism 135clinical details). These 10 patients come from 4 Turkish
families originating from Turkey and 2 Caucasian families
from The Netherlands. In summary, 8 of 10 cases showed
early-onset PLE characterized by hypoalbuminemia, hypo-
gammaglobulinemia, and intractable diarrhea, with 1 pa-
tient developing marked steatorrhea. Patients 7 and 8
presented with severe vomiting only, which resulted in
failure to thrive in the older sibling. Food containing fat
induced abdominal pain and vomiting soon after ingestion
and serum lipid profiles of the 10 patients were variable
(Supplementary Table 2). Some patients had normal
levels of serum TG, whereas 1 patient exhibited
hypertriglyceridemia. Most showed a reduced level ofFigure 2. DGAT1 protein expression in patient-derived material.
and patient 2 ileal and duodenal biopsy, respectively. (B) We
fibroblast lysate, but normal expression of DGAT1 in healthy con
(GAPDH) was used as a loading control. (C) Western blot showin
and normal DGAT2 protein level from Epstein-Barr virus–derived
control. GAPDH was used as a loading control. (D) Western bl
differentiated (DM) organoids from 2 healthy controls and patie
representative of 3 independent experiments.
Downloaded for Anonymous User (n/a) at ULAKBIM Academic  Bask
For personal use only. No other uses without permissionhigh-density lipoprotein, with normal levels of low-density
lipoprotein, very low-density lipoprotein, and cholesterol.
Endoscopy was performed on patients 1 to 3 and 7 to 10,
which showed no macroscopic abnormalities of the duo-
denum and colon (Supplementary Figures 1 and 2).
Histopathology of a duodenal biopsy from patient 1 showed
marked flattening of the villi (Figure 2 and Supplementary
Figure 2) and patient 3 showed marked shortening of the
villi (Supplementary Figure 1A), Electron microscopy of a
duodenal biopsy of patient 3 showed lack of microvilli
(Supplementary Figure 1A). Patients 7 and 8 showed normal
pathology, although the biopsies were taken under
fat-restricted diet (Supplementary Figure 1B). Duodenal(A) Immunohistochemistry of DGAT1 in control and patient 1
stern blot showing lack of DGAT1 and DGAT2 in patient 3
trol fibroblasts. Glyceraldehyde-3-phosphate dehydrogenase
g lower expression of potentially nonfunctional DGAT1 protein
B lymphoblastoid cell line of patient 4, a parent, and a healthy
ot for DGAT1 protein expression in undifferentiated (EM) and
nts 7 and 8. HSP90 was used as loading control. Results are
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plasmic CD10 staining (Supplementary Figure 1C), which led
to themisdiagnosis of atypical microvillus inclusion disease.22
Eight patients received various treatments that led to
resolution or significant improvement of the GI symptoms.
Most patients were placed on a fat-restricted diet, which
alleviated their GI symptoms. Addition of medium-chain TG
was tolerated, and some patients were infused with intra-
venous essential fatty acid supplements Intralipid and
Omegaven and fat-soluble vitamins. Patient 4 received
cholestyramine and patients 5 and 6 received pancreatic
lipase due to low fecal elastase level, both of which reduced
daily stool frequency. Patients 9 and 10 are twins and pa-
tient 9 received an intestinal transplant. The various treat-
ments and outcomes are summarized in Supplementary
Table 3.
Some patients developed extra-GI manifestations. In
patients 1, 2, and 6, recurrent episodes of unspecific
infections were recorded. Patients 9 and 10 had recurrent
episodes of septicemia due to catheter-related blood stream
infections. None of our patients showed any pattern of un-
usual or opportunistic infections that might be overtly
associated with fecal loss of immunoglobulins or lympho-
penia. Treatment of infections was successful with antibi-
otics, antifungal drugs, or prophylactic intravenous
immunoglobulin, as outlined in Supplementary Table 3.
Patient 5 had hepatomegaly and jaundice, and liver biopsy
revealed fibrosis and cholestasis. Patients 7 and 8 were
diagnosed with Gilles de la Tourette syndrome and were
treated with dexamphetamine.Identification of Novel DGAT1 Mutations
Whole-exome sequence analysis was performed in
patients 1, 3, 7, 8, 9, and 10, while targeted panel
sequencing was performed for patients 4 and 5. Variants in
affected siblings (patients 2 and 6) were identified using
conventional Sanger sequencing. Collectively, we identified
5 novel homozygous variants in the gene DGAT1 (Mendelian
Inheritance in Man: 604900, GenBank: NM_012079.5).
These variants segregated with the disease under the
assumption of autosomal recessive inheritance, with het-
erozygous carriers being unaffected (Figure 1A). The vari-
ants are neither present nor reported as rare heterozygous
variants in the gnomAD database,24 and were predicted to
be deleterious using Combined Annotation Dependent
Depletion25 prediction tool (Supplementary Table 1).
In family 1, we identified a homozygous nonsense
mutation at amino acid 401 leading to an early stop codon
(c.1202G>A, p.W401X). In family 2, we identified a homo-
zygous insertion deletion (c.573_574delAGinsCCCATCCC
ACCCTGCCCATCT) in exon 6 of DGAT1. In family 3, we
identified a homozygous splice site acceptor mutation
(c. 937-1G>A) preceding exon 12. In family 4, we identified
a homozygous single base-pair insertion, leading to a
frameshift and early stop codon (c.953insG, p.I319Hfs*31)
in exon 12. In families 5 and 6, we identified a homozygous
3 base-pair deletion (c.629_631delCCT, p.S210_Y211de-
linsY) in exon 7 (Figure 1, Supplementary Figure 3).Downloaded for Anonymous User (n/a) at ULAKBIM Academic  Bask
For personal use only. No other uses without permissionAltogether, we identified 5 novel disease-causing homozy-
gous mutations in DGAT1 in 6 patients of Turkish origin and
4 of Dutch origin.
Consequences of DGAT1 Mutations
We proceeded to study the consequences of DGAT1
mutation on available material. Immunohistochemistry on
GI biopsies from patient 1 and patient 2 showed a lack of
DGAT1 protein expression specifically in the epithelium of
the duodenum, ileum, and colon (Figure 2A and
Supplementary Figure 2), whereas DGAT1 protein was not
detected in the gastric mucosa of control or patient material
(Supplementary Figure 2). In patient 3, reverse-
transcription polymerase chain reaction of cDNA from
patient-derived fibroblast showed aberrant splicing
(Supplementary Figure 4), which ultimately led to unde-
tectable protein expression on Western blot (Figure 2B). In
patient 4, Epstein-Barr virus–derived B-lymphoblastic cell
line showed a highly reduced expression of DGAT1
(Figure 2C). Intestinal organoids derived from patients 7
and 8 showed normal mRNA levels on differentiation (data
not shown), but protein was absent (Figure 2D). Similar
data were obtained from patient 9 (data not shown).
Together, we show that all the novel DGAT1 mutations
identified led to aberrant protein expression.
To confirm that the DGAT1 c.629_631delCCT mutation
specifically leads to reduced DGAT1 protein levels without
affecting mRNA levels, Caco-2 cells were stably transfected
with Flag-DGAT1 WT or Flag-DGAT1 c.629_631delCCT.
Indeed, DGAT1 mRNA expression was similar in both cell
lines (Supplementary Figure 5A), but DGAT1 protein was not
detectable when DGAT1 was mutated (Supplementary
Figure 5B). Incubation with the proteasome inhibitor
MG132 shows that the loss of protein is at least partially due
to proteasomal degradation of the mutant DGAT1
(Supplementary Figure 5B). To further investigate the
increased proteasomal degradation of DGAT1
c.629_631delCCT, we determined the level of ubiquitination
of the mutant protein. Therefore, Caco-2 cells were
co-transfected with His-ubiquitin and Flag-DGAT1 WT or
Flag-DGAT1 c.629_631delCCT and treated with MG132. A
ubiquitin pulldown assay showed that ubiquitination of Flag-
DGAT1 c.629_631delCCT was increased compared with
ubiquitination of Flag-DGAT1 WT (Supplementary Figure 5C).
Loss of DGAT1 Leads to Aberrant
Lipid Metabolism
Free fatty acids (FFAs) can be processed for energy
production through beta oxidation, or stored in the form
of lipid droplets on its incorporation into TG. In enter-
ocytes, this lipid droplet formation is required for the
transport of long-chain FFAs into chylomicrons, before
being excreted across the basolateral membrane of
enterocytes. Recently, it was shown that DGAT1 mutant
fibroblasts accumulated less lipid droplets when incu-
bated with OA, an 18-carbon FFA.5 We hypothesized that
DGAT1 deficiency will lead to aberrant lipid droplet
formation in patient-derived cells.ent Universitesi from ClinicalKey.com by Elsevier on May 06, 2019.
. Copyright ©2019. Elsevier Inc. All rights reserved.
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lipids,19,26 on intestinal organoids from patients 7, 8, and 9
after 16 hours incubation with BSA-coupled OA. UsingFigure 3. Loss of DGAT1 results in decreased lipid droplet
40,6-diamidino-2-phenylindole (DAPI) (blue) and LD540 (yellow
patient 8 (P8) and DGAT1KO organoids after 17-hour incubation
DGAT1 inhibitor (OAþDGAT1i). Representative images of 3 he
genome-edited DGAT1-knock-out (DGAT1KO) organoids. (B)
organoids from controls, patients, and DGAT1KO organoids a
accumulate lipid droplets and show increased SSC and LD540,
cells. Mean fluorescence intensity (MFI) of SSC and LD540 was p
a 2-way analysis of variance with Tukey’s multiple comparison
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For personal use only. No other uses without permissionfluorescence imaging,weobserved an increase in lipid droplet
formation in healthy control organoids, which was signifi-
cantly reduced in DGAT1 mutant patient-derived organoidsformation in organoids. (A) Immunofluorescent images of
) staining of organoids from healthy control, DGAT1 mutant
with vehicle control (BSA), 1 mM OA, or 1 mM OA þ 0.1 mM
althy controls, 3 patients (patients 7–9), and 3 CRISPR/Cas9
Representative histograms of SSC and LD540 staining in
s described in (A). Upon OA stimulation, control organoids
which was severely reduced in patient-derived and DGAT1KO
lotted for n ¼ 3 per group. Statistical analysis was done using
test. Mean ± SD is indicated; * P .05, *** P .001.
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organoids that were generated using CRISPR/Cas9 genome
editing forDGAT1 in healthy control organoids (Figure 3A and
Supplementary Figure 6 and Supplementary Table 4). For-
mation of lipid droplets was at least partially dependent on
DGAT1, as the use of a selective DGAT1 inhibitor (DGAT1i)
AZD 3988 on healthy control organoids resulted in a reduc-
tion of lipid droplet accumulation as shown by decreased
LD540 staining (Figure 3A). This was further confirmed and
quantified using a flow cytometry–based assay, in which
healthy control organoids showed an increased granularity
due to the accumulation of lipid droplets (side scatter area,
SSC-A) and increased LD540 staining on incubation with OA.Figure 4. Loss of DGAT1 results in decreased lipid droplet form
forward (FSC-A) and SSC-A of patient 3 and 2 control fibrobl
technical replicates. (B) Left: Representative histogram of Nile
control fibroblasts with and without OA addition. Right: MFI o
mediated delivery of exogenous DGAT1 and DGAT2 on patie
staining on patient 3 fibroblasts reconstituted with empty vector
using 2-way analysis of variance with Tukey’s multiple compari
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caused a significant reduction in granularity and LD540
staining compared with healthy controls (Figure 3B).
In addition, we incubated normal donor and patient 3–
derived fibroblasts with OA and quantified lipid droplet
formation by flow cytometry. Normal donor fibroblasts
accumulated lipid droplets on incubation with OA, which
was shown by increased granularity (SSC-A) and Nile Red
staining, a dye that binds to neutral lipids such as TG.27 In
contrast, patient-derived dermal fibroblast from patient 3
failed to accumulate lipid droplets, as they showed a lack of
granularity (Figure 4A) and Nile Red staining (Figure 4B). In
addition, we show that this lack of lipid droplet formationation in fibroblasts. (A) Left: Representative contour plots for
asts with and without OA addition. Right: Mean SSC-A of 5
Red mean fluorescence intensity (MFI) of patients 3 and 2
f 5 technical replicates. (C) Western blot showing retroviral-
nt 3 fibroblasts. (D) Mean SSC-A and (E) MFI of Nile Red
(EV), WT DGAT1, or WT DGAT2. Statistical analysis was done
son test. Mean ± SD is indicated; **P < .01 or ****P < .0001.
ent Universitesi from ClinicalKey.com by Elsevier on May 06, 2019.
. Copyright ©2019. Elsevier Inc. All rights reserved.
July 2018 DGAT1 Deficiency Impairs Lipid Metabolism 139
BA
SI
C
AN
D
TR
AN
SL
AT
IO
NA
L
ATwas not detected in B-LCL derived from patient 4
(Supplementary Figure 7), presumably due to the expres-
sion of DGAT2 in this cell type (Figure 2).
WT DGAT1 and DGAT2 Rescues Lipid Droplet
Formation in DGAT1 Deficiency
We reconstituted fibroblasts from patient 3 with WT
DGAT1 and DGAT2 protein using a retroviral delivery system.
We successfully reconstituted DGAT1 protein expression, and
overexpressed DGAT2 in these cells (Figure 4C). The DGAT1-
reconstituted fibroblasts were able to incorporate OA into
lipid droplets as seen by the increased granularity and
increased Nile Red fluorescence (Figure 4D and E). The
phenotype was also rescued by overexpression of DGAT2,
resulting in restored granularity and Nile Red staining on
addition of OA (Figure 4D and E). We concluded that recon-
stitution of DGAT1 rescues the altered lipid metabolism
phenotype, and that DGAT2 can partially rescue altered lipid
droplet formation in DGAT1-deficient fibroblasts.
Loss of DGAT1 Specifically Inhibits TG Formation
To substantiate the specificity of DGAT1 deficiency for
causing aberrant TG formation, we performed thin layer
chromatography to measure the levels of TG and DG in
organoids derived from 3 healthy controls and patients 7, 8,
and 9 (Figure 5A). By quantification of respective DG and TG
band intensities, we determined that the TG/DG ratio in
healthy control organoids was significantly higher
compared with patient-derived organoids (Figure 5B).
These results indicate a DGAT1-dependent loss of TG syn-
thesis in patient-derived intestinal organoids, whereas
levels of DG were comparable.Figure 5. Loss of DGAT1
results in decreased tri-
glyceride (TG) formation.
(A) Organoids from 3
healthy controls and pa-
tients 7, 8, and 9 were
grown in EM for 7 days.
Lipid extracts were iso-
lated and run by thin layer
chromatography to deter-
mine levels of diac-
ylglycerol (DG) and
triglyceride (TG). Relative
positions were indicated
by reference samples for
DAG and TG. (B) Ratio of
intensity of TG over DAG
for each sample. Statistical
analysis was done using a
Mann-Whitney U test.
Mean ± SD is indicated,
*P < .05.
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Sensitivity to Lipid-induced Toxicity
Most DGAT1-deficient patients reported in this study
suffered from PLE after ingestion of dietary lipids, which
can be the result of either intestinal mucosal injury or
lymphatic abnormalities.28 To assess whether exposure to
lipids leads to mucosal injury in DGAT1-deficient patients,
we performed lipotoxicity assays in healthy control and
DGAT1-deficient organoids. We incubated the organoids
with varying concentrations of BSA-coupled OA in EM and
assessed cell death by brightfield microscopy and propi-
dium iodide staining (Figure 6A). Remarkably, we observed
100% cell death at 4 mM OA in patient-derived organoids,
whereas cell death was still almost absent at 6 mM OA in
control organoids. To further quantify these findings, we
determined lipid-induced caspase-mediated cell death using
a Caspase-Glo 3/7 assay. We show that DGAT1-deficient
cells are more sensitive to lipotoxic stress compared with
healthy control organoids and undergo programmed cell
death on treatment with OA (Figure 6B). By nonlinear
regression analysis, the median lethal dose was determined
to be approximately 7 mM OA for healthy control organoids
and 4 mM OA for patient-derived organoids (P < 0.001).
Overall, these results indicate that DGAT1-deficient orga-
noids are more susceptible to lipid-induced toxicity, which
may reflect the clinical feature of PLE in DGAT1-deficient
patients that occurs on ingestion of fat.Discussion
Lipid metabolism is an important physiological function
within the human body that includes the digestion and ab-
sorption of lipid products from food. Inborn errors of lipident Universitesi from ClinicalKey.com by Elsevier on May 06, 2019.
. Copyright ©2019. Elsevier Inc. All rights reserved.
Figure 6. Loss of DGAT1
results in increased sensi-
tivity to lipotoxic stress.
Organoids of 3 healthy
controls and 3 patients
(7–9) were grown in EM
and incubated overnight
with a range of oleic acid
(OA) concentrations. (A)
Representative images
showing brightfield and
propidium iodide staining
for cell death of the orga-
noids after incubation with
OA. (B) Caspase-Glo 3/7
assay for apoptotic cells
after incubating organoids
with OA. Samples were
normalized for vehicle
control values and the
maximum value for each
sample was set to 100%
assay response. Median
lethal dose (LD50) was
calculated by regression
analysis. Statistical anal-
ysis on LD50 values was
done using a Student’s t
test, ***P  .001.
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neurological impairment to hypertriglyceridemia. Recently,
lipid metabolism disorders have been linked to CDD, such as
in the case of Niemann-Pick disease type C with inflamma-
tory bowel disease due to impaired autophagy.29 In the case
of cytoplasmic TG metabolism disorders, none of the other
deficiencies have been reported to develop any GI
phenotype.30
Previous studies on DGAT1 deficiency have identified a
total of 3 distinct homozygous and 2 compound heterozy-
gous mutations in DGAT1.3–6 These patients suffered fromDownloaded for Anonymous User (n/a) at ULAKBIM Academic  Bask
For personal use only. No other uses without permissionsevere congenital diarrhea and PLE, clinical features that are
shared with most of our patient cohort. Although this shared
phenotype further confirms the involvement of DGAT1 in
intestinal failure, limited functional data or potential ther-
apeutic options have been reported thus far.
Currently, there is no genotype-phenotype correlation in
DGAT1 deficiency, as patients develop varied clinical history
ranging from complete resolution of GI symptoms to a lethal
course of disease. As previously described and also
observed in our study, discordant phenotypes associated
with identical mutations in siblings and in different,ent Universitesi from ClinicalKey.com by Elsevier on May 06, 2019.
. Copyright ©2019. Elsevier Inc. All rights reserved.
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non, as well as the novel clinical features, such as normal
serum TG and hepatic involvement, observed in our patients
indeed extend the spectrum of the clinical phenotype of
DGAT1 deficiency, or are unspecific secondary effects of
treatment, cannot be inferred from our study. By analogy,
the unsatisfactory clinical outcome described for patient 9
after the small bowel transplantation may be attributed to
known posttransplant complications rather than unsuc-
cessful correction of the DGAT1 deficiency in the intestine.
To provide further insight into the pathomechanism of
DGAT1 deficiency, we have produced cell models that
recapitulate an altered lipid metabolism in vitro. Here, we
show that patient-derived organoids can recapitulate the
molecular pathomechanism of DGAT1 deficiency. We have
demonstrated aberrant lipid metabolism as evidenced by
reduced lipid droplet and TG formation on incubation with
OA in both patient-derived organoids and fibroblasts. In
addition, we show for the first time that DGAT1-deficient
cells are more susceptible to lipid-induced toxicity, which
provides a plausible explanation for the clinical PLE symp-
toms in DGAT1 deficiency and possibly other forms of PLE,
such as primary intestinal lymphangiectasia.31 The fact that
dietary fat restriction can even restore normal fecal protein
clearance in PLE further supports the concept that cellular
lipotoxicity may be one of the driving forces for ongoing
fecal protein loss in untreated PLE. Whether this
lipotoxicity-induced enterocyte dysfunction is caused by
endoplasmic reticulum stress or induced autophagy, which
has been implicated in lipid metabolism disorders such as
Niemann-Pick disease type C with inflammatory bowel
disease,29 remains to be determined. Moreover, elucidation
of the precise role of DGAT1 in common lipotoxicity-related
diseases, such as type 2 diabetes, nonalcoholic fatty liver
disease, and metabolic cardiomyopathy, may be the first
step toward new therapy strategies for obesity-related
disorders.
Of note, the novel technology of patient-derived intesti-
nal organoids provided an unprecedented look into patho-
biology of the cells in the GI tract. In the future, a more
systematic use and collection of organoids from potential
DGAT1 deficiency and other patients with intestinal failure
will allow for better dissection of the disease mechanism
involving the gut epithelium.
As described in this study and in previous literature,
DGAT1-deficient patients usually do well on a fat-restricted
diet. An early introduction of such a diet might even have
prevented the development of a full-blown PLE in patients 7
and 8. In addition, the administration of short chain fatty
acid proves to be a good supplement to the diet for some
patients. Intravenous administration of essential fatty acid
was also well-tolerated, presumably as it bypasses absorp-
tion through the gut epithelium as well. Whether patients
benefit from novel ways of treatment with available drugs,
such as cholestyramine and pancreas enzymes, as empiri-
cally applied for patient 4 and patients 5 and 6, respectively,
would have to be attempted and evaluated in additional
patients and in carefully designed trials. Before treatment,
neither diagnosis of bile acid diarrhea nor exocrine pancreasDownloaded for Anonymous User (n/a) at ULAKBIM Academic  Bask
For personal use only. No other uses without permissioninsufficiency was formally tested or firmly established,
because the observation of slightly decreased fecal elastase
levels may be unspecific due to fecal dilution in severe
chronic diarrhea. Although the course of disease evidently
can be mild, early diagnosis of DGAT1 remains vital, as all
patients were severely ill during the first few months of life
and thus far one patient suffered from a lethal course of
disease. Additionally, the impact on the quality of life during
chronic treatment (monthly infusions or through a central
line that includes risks of infections) and the variable
genotype-phenotype relationships of DGAT1 patients should
not deter the search for new therapeutic options for these
patients.
In pursuit of possible therapeutic strategies, we deter-
mined that proteasome inhibitors could provide a potential
therapeutic option in case of proteasome-mediated protein
degradation, as shown for the mutation in families 5 and 6
(Supplementary Figure 4). In addition, we determined that
DGAT2 might be able to compensate for the lack of DGAT1
function. DGAT2 is an isozyme of DGAT1 that does not share
any homology in protein sequence or domains.11 However,
DGAT2 shares functional characteristics with DGAT1, cata-
lyzing the formation of TG from DG and fatty acyl-CoA in the
liver. In this study, we show that DGAT2 might be able to
compensate for this phenotype, as shown by OA addition on
DGAT2-expressing B-LCL and exogenous expression of
DGAT2 in DGAT1-deficient fibroblasts. A single heterozy-
gous, autosomal dominant DGAT2 mutation has been
described in a family with Charcot-Marie-Tooth syndrome,32
but no GI involvement was reported, possibly because
DGAT2 is not highly expressed in the human intestine.3
Therapeutic strategies to induce DGAT2 expression might
potentially provide an additional, viable treatment strategy
in DGAT1 deficiency.
Previous studies performed with Dgat1/ mice impli-
cated a beneficial role of DGAT1 inhibition in obesity
through changing metabolic landscapes.33–35 These studies
resulted in the development of DGAT1 inhibitors for use in
human obesity.36 However, participants in a clinical trial of
DGAT1 inhibitor Pradigastat developed side effects of
diarrhea and nausea,37,38 similar to the phenotype of DGAT1
deficiency. Dgat1/ mice did not develop a GI phenotype,
presumably due to the intestinal expression of DGAT2
and diacylglycerol transacylase, which might compensate
for the lack of DGAT1.39 Our data suggest that in humans,
lack of TG formation and packaging is detrimental in the
context of GI epithelium, and that a serious note of caution
on the clinical use of DGAT1 inhibitors should be provided.
This finding accentuates the lack of available knowledge of
intestinal lipid uptake and metabolism, and emphasized
how the use of clinically relevant in vitro systems can help
to fill this gap.
In summary, we here described a large cohort of DGAT1-
deficient patients, and extended our knowledge of the
pathomechanism of DGAT1 deficiency. Our findings expand
the differential diagnosis of vomiting and congenital diar-
rhea in neonates. Clinicians should maintain a high suspi-
cion for DGAT1 deficiency in cases of unexplained vomiting,
especially when associated with failure to thrive and PLE,ent Universitesi from ClinicalKey.com by Elsevier on May 06, 2019.
. Copyright ©2019. Elsevier Inc. All rights reserved.
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essential fatty acids and fat-soluble vitamins as a first line of
therapy. In conclusion, the findings described in this article
show that DGAT1 mutations not only cause congenital
diarrhea and PLE, but are also linked to fat intolerance.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at https://doi.org/10.1053/
j.gastro.2018.03.040.References
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Supplementary Clinical Description of
the 10 Patients
Patient 1 presented with watery, nonbloody, nonmucoid
diarrhea that commenced immediately after birth. He was
severely dehydrated; breast milk was discontinued and
changed to lactose-free formula, but diarrhea persisted. A
diagnosis of microvillus inclusion disease (MVID) was
considered after endoscopic biopsy. At 25 days of age, pa-
tient 1 was admitted to another hospital, where he required
recurrent albumin infusions (AIs) to correct the hypo-
albuminemia. Immunological tests were normal except for
slight decrease in immunoglobulin (Ig)G and IgM. Fat-
soluble vitamins A, D, and E levels were low. Stool stea-
tocrit was positive. Infection, food allergy, cystic fibrosis,
and prohormone convertase deficiency had been excluded
by appropriate laboratory tests. A second endoscopy and
colonoscopy were performed, and the previous endoscopic
biopsy was reanalyzed. Congenital enteropathies (Tufting
enteropathy, MVID, inflammatory bowel disease, autoim-
mune enteropathy, and food-protein–induced enteropathy)
were excluded. Treatment with amino acid–based formula
was not effective, but a slight clinical improvement was
observed with basic casein hydrolysate and galactomin 19
formula. He was discharged at 4.5 months of age with some
weight gain. Diarrhea and vomiting persisted after his
discharge at home, and 2 weeks later, he was referred to the
current attending physician for dehydration, weight loss
(470 g over 15 days), severe hypoalbuminemia (1.8 g/dL),
hyponatremia (130 mEq/L), and hypokalemia (3 mEq/L).
On admission, he was malnourished (weight 3680 g [<3%],
height 58.5 cm [3%]) and severely dehydrated. Fluid
replacement therapy, AI, and total parenteral nutrition
(TPN) were started. Laboratory tests showed low serum IgG
1.53 g/L (3.04–12.31), total cholesterol 63 mg/dL, high-
density lipoprotein (HDL) 25 mg/dL, low-density lipopro-
tein (LDL) 12 mg/dL, very low-density lipoprotein (VLDL)
27 mg/dL, triglyceride 135 mg/dL, and vitamin B12 101
ng/mL and steatorrhea was observed. Workup included
extensive infectious, immunologic, and hormonal studies, all
of which were negative or normal. Upper gastrointestinal
endoscopy and ileocolonoscopy, biopsies, and electron mi-
croscopy were normal. During his hospitalization, bulky,
watery, and greasy diarrhea was observed, and Sudan stain
of stool continuously revealed massive droplets of fat.
Basic-F (fat-free formula [FFF]) was started for fat malab-
sorption, and within 3 weeks, a dramatic improvement and
subsequent complete resolution of his symptoms was
observed and further TPN was not needed. Extensively
hydrolyzed formula rich in medium-chain triglyceride
(MCT) was gradually added to the FFF. He was discharged
at 7 months of age with a combination of these formulas.
During the follow-up, solid food with daily MCT oil sup-
plementation was commenced gradually. The child exhibi-
ted elevated fasting triglyceride level (207 mg/dL) at 8
months of age, which was decreased with adding omega-3
fatty acids. Due to recurrent episodes of vomiting, cough,
and otitis media during follow-up, long-term prophylactic
antibiotic with sulfamethoxazole-trimethoprim was added
at 12 months of age. He is currently 4 years and 4 months
old, with normal growth and development with the com-
bination of low-fat–age-appropriate diet, MCT supplemen-
tation, and FFF.
Patient 2, a sibling of patient 1, also presented with
nonbilious vomiting and watery, nonbloody, nonmucoid
diarrhea 2 to 3 times a day and required repeated hospi-
talizations for dehydration due to diarrhea. At 5 months, she
was referred to a tertiary hospital due to failure to thrive,
peripheral edema, and severe hypoalbuminemia (1.8 g/dL,
reference 3.2–5.0 g/dL). The stool was negative for leuko-
cytes. Standard laboratory tests, including urinalysis; acute-
phase reactants; serum IgA, IgM, and IgE; serum and urine
amino acids; artery blood gases; tandem mass spectros-
copy; and thyroid function tests were normal. Serum IgG
level was slightly reduced (204 mg/dL, reference 304–1230
mg/dL). Serum lipid profile was normal. Triglyceride level
was 84 mg/dL (reference <150 mg/dL), total cholesterol
62 mg/dL (reference <170 mg/dL), LDL 28 mg/dL (refer-
ence <110 mg/dL), HDL 18 mg/dL (reference 40–60 mg/
dL), VLDL 16 mg/dL (reference <30 mg/dL). Upper
gastrointestinal endoscopy and biopsy were normal. She
required recurrent AIs to correct the hypoalbuminemia and
died at 6 months of age due to sepsis.
Patient 3, a female infant with lack of dysmorphic fea-
tures, was born via vaginal delivery at 39 weeks of gestation
following an uneventful prenatal history, weighing 3500 g,
measuring 48 cm body length and 35 cm head circumfer-
ence at birth. The healthy Turkish parents were not aware
of a consanguineous relationship but share geographical
origin. This small village was founded by the children of 3
siblings, collectively indicating parental consanguinity. A
sister of the patient’s father died at the age of 11 months
from vomiting and diarrhea. Apart from that, family history
was inconspicuous. Because of watery diarrhea (7 times a
day, 150 g/kg per day) starting at the age of 3 weeks,
weight loss, and severe dystrophy, she was admitted to a
pediatric clinic weighing 3400 g. Parenteral nutrition was
immediately started and the patient was also continuously
fed through a nasogastric catheter. Stool analyses showed
normal values for a1 antitrypsin (13 mg/dL, reference 90–
200 mg/dL), fecal elastase (>500 mg/dL, reference >200
mg/g), stool sodium (66 mmol/L, reference 20–25 mEq/L)
and potassium (31.7 mmol/L, reference 50–75 mEq/L),
excluding congenital sodium and chloride diarrhea. Serum
bile acids were mildly increased (38,9 mmol/L, reference
<10 mmol/L), amylase 7 U/L (reference <30 U/L) and
lipase 13 U/L (reference 13–60 U/L) were normal. Unfor-
tunately, no information on fecal bile acid levels is available.
The patient exhibited hypoproteinemia (3.5–4.7 g/dL,
reference 5.7–8.7 g/dL) and hypoalbuminemia (2.2–2.7 g/
dL, reference 3.2–4.7 g/dL). Metabolic screening was
without pathological findings. Stool cultures as well as po-
lymerase chain reaction (PCR) for adenovirus, rotavirus,
and enterovirus in the stool were negative. Serum immu-
noglobulin levels were normal. Food mix allergen-specific
IgE in serum was negative. A gastroduodenoscopy per-
formed at the age of 3 months showed duodenal microvillus
atrophy. Light microscopy analysis of the biopsy of the
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duodenum excluded enteric anendocrinosis. Electron mi-
croscopy revealed a deteriorated integrity of the microvilli,
and no microvillus inclusions (Supplementary Figure 1).
The patient continuously failed to thrive, and at the age of
11 months, kidney stones of several millimeters in diameter
were found, along with lower-extremity edema, corneal
cystine crystal accumulation, and metabolic acidosis. Renal
function tests and urine analyses were repeatedly normal,
and leukocyte cysteine levels were normal with 0.047
nmol/mg protein (0–0.3 nmol/mg). The patient received 1
g/kg albumin every other day due to protein-losing enter-
opathy and decreasing albumin values. She was fed via a
nasogastric tube on elemental and semi-elemental formula.
Additionally, parenteral nutrition (protein 2 g/kg per day
and lipid 1 g/kg per day) was administered. A second
endoscopy of the upper gastrointestinal tract was per-
formed due to persisting diarrhea. Because milky deposits
(lipid accumulation) were seen in the duodenum, chylomi-
cron retention disease and abetalipoproteinemia were
considered. The patient’s triglyceride levels were increased
(up to 370 mg/dL [0–150 mg/dL]), whereas total choles-
terol was in the normal range (96 mg/dL [0–200 mg/dL])
and HDL and LDL were decreased (HDL 9.5 up to 22 mg/dL
[40–60 mg/dL], LDL 23 mg/dL [60–130 mg/dL]). The
patient’s parents’ lipid profiles were normal.
At this point, whole-exome sequencing established the
diagnosis of a congenital protein-losing enteropathy due to
DGAT1 mutation. Subsequently, oral MCT administration
was started. Parenteral nutrition support continued. Sub-
sequent to observing hypocalcemia, secondary hyperpara-
thyroidism was diagnosed (parathyroid hormone: 312 pg/
mL, reference 15–65 pg/mL, 25-hydroxyvitamin D 18 ng/
mL, reference 25–80 ng/mL, calcium 6.5 mg/dL, reference
8.7–10.4 mg/dL), and vitamin D and calcium supplemen-
tation was initiated. The patient is now 13 months old. The
stool amount declined from 150 g/kg per day during the
first application to 100 g/kg per day in the past 3 months.
The stool frequency decreased from 7 times a day to 3 to 4
times a day. She weighs 3850 g (<3 percentile), is 57 cm
(<3 percentile) long, and has a head circumference of 38
cm (<3 percentile). She vomits 3 to 4 times every day, has
extreme flatulence and abdominal distention. Parenteral
nutrition support continues. For this purpose, the patient is
hospitalized for 3 to 4 weeks and then she has a maximum
break of 1 week without parenteral nutrition. Her psycho-
motor development is compatible with 3 to 4 months.
Targeted gene sequencing had excluded infantile neph-
ropathic cystinosis, and whole-exome sequencing excluded
microvillus inclusion disease and variants in other known
genes causing isolated and syndromic forms of congenital
diarrheas.
Patient 4 was referred to the attending physician due to
intractable diarrhea, which started when he was 2 months
old. Intestinal and colonic endoscopic and histopathological
investigations were normal. Infectious, metabolic disorders,
malignancies, cystic fibrosis, and congenital glycosylation
defect were excluded. Longitudinal measurement of lipid
profile showed normal levels of total cholesterol, LDL, HDL,
VLDL, and triglyceride. Serum immunoglobulin levels were
normal. He had marked clinical improvement on treatment
with cholestyramine, which resulted in the reduction of
stool volume and frequency. At the latest follow-up, the
patient weight is at 9.5% and height is at 4.5% of Turkish
boys. He does not have any vomiting or diarrhea and is still
on cholestyramine treatment.
Patient 5 was born at term to consanguineous parents.
He was hospitalized at 40 days of age because of vomiting,
bloody diarrhea, and failure to thrive. He was started on
amino acid–based formula due to a suspected cow milk
allergy. At the age of 5 months, abdominal and cranial
ultrasonography were normal and upper gastrointestinal
endoscopy and biopsy revealed nonspecific results. He had
low IgA, IgM, and IgG levels. At a follow-up, the patient was
found to have low serum albumin (2.2g/dL, normal 3.2 g/
dL) and total protein. At 1 year of age, he was referred to
the current attending physician because of hepatomegaly
and jaundice for a liver biopsy. He is below the third
percentile in height and weight. Physical examination
revealed abdominal distention, cutis marmoratus, 8 cm
length of liver below the right costal margin. Laboratory
assessment of liver function and immunoglobulin levels
were as follows: aspartate aminotransferase 240 U/L,
alanine aminotransferase 111 U/L, g-glutamyltransferase
335 U/L, total/direct bilirubin levels 2.95/2.05 mg/dL,
serum IgA 1.59 g/L, IgM 1,14 g/L, IgG 9.14 g/L. He has
watery stools 4 to 5 times per day. He also has milk protein
intolerance (bloody diarrhea occurs after formula feeding).
Liver biopsy revealed hepatocanalicular and ductular
cholestasis, paucity of bile ducts, mixed type hep-
atosteatosis (10%), porto-portal fibrosis, and fibrotic
activity of 3/6. His daily stool frequency had reduced with
the administrations of pancreatic enzymes (Creon), but his
weight and height are below the third percentile.
Patient 6, a sibling of patient 5, was admitted to hospital
when he was 2.5 months of age because of watery diarrhea
(at least 10 times a day). He presented hyponatremia,
hypochloremia, hypoalbuminemia, hypocalcemia. Sweat
chloride test was normal. His daily stool frequency had
reduced with the administrations of pancreatic enzymes
(Creon), but he had recurrent infections and was hospital-
ized. He was also placed on amino acid–based formula.
Endoscopy and colonoscopy was normal at the age of 2
years. Duodenum biopsy revealed focal vacuolization at one
area and partially blunted villi. Colon biopsy was normal.
Liver profile: aspartate aminotransferase 149 U/L, alanine
aminotransferase 56 U/L g-glutamyltransferase 70 U/L.
Total serum protein was normal (4.38 g/dL), but low
albumin level (2.59 g/dL) was observed. He has low IgA
serum level but normal IgG and IgM levels. Free thyroxine–
thyroid stimulating hormone levels were normal. His lipase
and amylase levels were within normal range (13/46 U/L
respectively). Lipid profile revealed low HDL 21 mg/dL
(40–60 mg/dL), LDL 14 mg/dL (<130 mg/dL), VLDL 36
mg/dL (<40 mg/dL), triglyceride 184 mg/dL (<200 mg/
dL), and normal total cholesterol 59 mg/dL (<200). Vitamin
E level was deficient, but vitamin A and D levels were
normal. He had bilateral nephrocalcinosis on abdominal
ultrasonography. Urine organic acid analysis and serum
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amino acid chromatography were normal. After 2 years of
age, his symptoms improved spontaneously, and he was lost
to follow-up afterward. His weight is now 16 kg (<third
percentile), height 104 cm (<third percentile).
Family 5 is a consanguineous Dutch family, with the
parents sharing ancestors 7 generations ago, and consists of
3 brothers of which 2 were affected (patients 7 and 8). The
oldest boy (patient 8) presented in the first month of life
with vomiting and failure to thrive. Physical examination
showed a dystrophic boy without further abnormalities, and
a normal serum albumin (4.35 g/dL). A scintigraphy was
performed, which showed delayed gastric emptying.
Extensive additional research did not reveal a diagnosis.
Initially the patient was treated with TPN, which reversed
the symptoms. By experiment, a fat-restricted diet was
introduced at the age of 7 months, which enabled enteral
feeding again. Incidental ingestion of low amounts of fat
causes abdominal pain and vomiting within 1 hour after
ingestion. The boy currently receives bimonthly infusions of
Intralipid and Omegaven and supplementation of fat-
soluble vitamins, leading to normal plasma levels of fat-
soluble vitamins and fatty acids, except for linoleic acid,
which is just below normal. He was diagnosed with Gilles de
la Tourette syndrome at the age of 7 years, which was
treated with dexamphetamine. The younger brother
(patient 7) presented with vomiting in the first days of life,
which was reversed after immediate introduction of a fat-
restricted diet. Like his brother, he is supplemented with
fat-soluble vitamins and monthly infusions of Intralipid and
Omegaven, leading to normal plasma levels of fat-soluble
vitamins and fatty acids, except for marginally decreased
levels of linoleic acid. He was also diagnosed with Gilles de
la Tourette syndrome.
Family 6 is a Dutch family of unknown consanguinity,
which consists of a monozygotic female twin pair and a
male sibling of which the twin pair was affected, patients 9
and 10. They were born after a pregnancy of 34 6/7 weeks.
Patient 9 had a birth weight of 2540 g and a bilateral
clubfoot. During the first week of life, she developed severe
watery diarrhea on bottle feeding. This subsided after a
short period with TPN after which she tolerated full enteral
feeding on Neocate for some months. However, the diarrhea
returned and was accompanied by severe vomiting, also
after small amounts of oral feeding. Therefore, enteral
feeding was stopped and she was totally dependent on TPN.
Protein-losing enteropathy (PLE) was present with a high
fecal alpha-1-antitrypsin (9.1 mg/g feces, reference 0.0–1.1
mg/g feces) and a low serum albumin (23.8 g/L, reference
36–42 g/L). Microscopy of the small intestinal mucosa
showed minimal villus atrophy, with generally a normal
brush border on periodic acid-Schiff staining, but with un-
specific CD10-positive globules in the cytoplasm of the
enterocyte. As numerous microvilli were seen on the lateral
membranes of the enterocyte, a misdiagnosis of variant
microvillus inclusion disease was made. Given this diag-
nosis, and the dependence on TPN, she received a small
bowel transplantation at the age of 3.5 years. After the small
bowel transplantation, TPN was stopped and polymeric
enteral nutrition was tolerated. Her clinical course after
small bowel transplantation was complicated by post
transplantation lymphoproliferative disease, autoimmune
problems, and recurrent (pulmonary) infections. Currently,
she is malnourished and still stunted despite a high caloric
diet with a polymeric formula for which we started addi-
tional parenteral nutrition. After small bowel trans-
plantation, it is sometimes difficult to unequivocally define
the origin of failure to thrive, which could be related to at
least partially ongoing disease, side effects of immunosup-
pression, or difficulties in reestablishment of sufficient
enteral nutrition necessary to promote catch-up growth.
Clinically, we do not have hints for persisting PLE following
partial correction of intestinal DGAT1 deficiency due to
isolated small bowel transplantation, and intestinal biopsies
did not show signs of chronic rejection.
The identical twin sister, patient 10, had a birth weight
of 1745 g without any congenital abnormalities. She had the
same clinical course as her sister. She also developed severe
watery diarrhea on bottle feeding in the first week of life,
which subsided on TPN. Subsequently she was fed with
Neocate for some months. As her twin sister, she presented
with watery diarrhea and vomiting at the age of 5 months,
for which enteral feeding was stopped and she was totally
dependent of TPN. Results of laboratory investigations were
very similar to her sister, with a PLE and an intestinal
histology that suggested the diagnosis of atypical MVID. She
was also put on the waiting list for small bowel trans-
plantation. However, during the waiting list period (and
after the transplantation of her sister) enteral feeding was
successfully reintroduced with carbohydrates (first) and
proteins (secondly), whereas the introduction of fats was
complicated by motility problems (vomiting). At first, she
did not tolerate MCT ingestion at all (vomiting directly after
ingestion), but MCT was tolerated within months. Long-
chain triglycerides were tolerated only in small amounts
and oral supplementation of docosahexaenoic acid and
amino acids were tolerated. After 4 months, she was not
dependent on TPN anymore and she was taken off the
waiting list for small bowel transplantation. Her diet con-
sisted of a mixture of Hydrolyzed Whey Protein/Malto-
dextrin mix, Fantomalt, Liquigen, Calogen, Phlexy-vits, and
Key Omega. We tried to switch to a standard oligomeric
feeding formula after 2 years, but she did not tolerate this.
Although she tolerated enteral feeding, she was still stunted
and PLE was still present. For this reason, we recently
started a fat-free diet with enteral supplementation of fat-
soluble vitamins and monthly intravenous infusions of
SMOF lipids.
Supplementary Materials and Methods
Cell Culture
Crypts were isolated from biopsies as described previ-
ously1 and resuspended in medium without growth factors
(GF), consisting of Advanced Dulbecco’s modified Eagle’s
medium/F12 (Gibco, Waltham, MA), 100 U mL1 penicillin-
streptomycin (Gibco), 10 mM HEPES (Gibco), and Glutamax
(Gibco). Matrigel (Corning, Tewksbury, MA) was added to a
final concentration of 70% and plated on prewarmed cell
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culture 24-well plates (Corning). After matrigel polymeri-
zation, organoid culture medium (human small intestine
expansion medium [hSI-EM]) was added consisting of GF-
medium, 50% Wnt-conditioned medium, 20% Rspondin-1-
conditioned medium, 10% Noggin-conditioned medium,
50 ng/mL murine epidermal growth factor (PeproTech,
Rocky Hill, NJ), 10 mM nicotinamide (Sigma), 1.25 mM N-
acetyl (Sigma), B27 (Gibco), 500 nM TGF-a inhibitor A83–
01 (Tocris, Bristol, UK), 10 mM P38 inhibitor SB202190
(Sigma), and 100 mg/mL Primocin (InvivoGen, San Diego,
CA). During experiments, Primocin was left out. Organoids
were cultured in 37C and 5% CO2 and medium was
refreshed every 2 to 3 days. The organoids were passaged
1:3 to 1:6 every week after mechanical disruption or 1:10 to
1:20 as single cells (Trypsin/EDTA or TrypLE Express). For
single cells, 10 mM ROCK inhibitor Y-27632 (Abcam, Cam-
bridge, UK) was added for the first 2 to 3 days of the cul-
ture. To induce differentiation, organoids were cultured in
differentiation medium (hSI-DM, which is hSI-EM lacking
WNT3A, nicotinamide, and SB202190) for 5 days, as
described previously.1
Immunohistochemistry
Biopsies obtained from patients and siblings were either
freshly or previously mounted onto glass slides. Staining
was done using a standard immunohistochemistry protocol
with the Lab Vision UltraVision LP Detection System: HRP
(horseradish peroxidase) Polymer (Ready-To-Use) (TL-060-
HL; Thermo Scientific, Waltham, MA) DGAT1 protein was
detected using a rabbit polyclonal IgG (H-255; Santa Cruz
Biotechnology, Inc., Dallas, TX) at 1:400 dilution.
CRISPR/Cas9 Knockout of DGAT1
Corresponding DNA-oligos were ligated into the plasmid
vector pSpCas9(BB) (Addgene PX459). Before transfection,
the organoids were primed by removing WNT3A and
Rspondin-1 and addition of 5 mM CHIR99021, 1.25%
dimethyl sulfoxide, and 10 mM Y-27632 (ROCK inhibitor) to
the culture medium as described previously.2 For trans-
fection, 1  106 single cells in 80 mL BTXpress buffer (BTX
Genetronics, Holliston, MA) were mixed with 10 mL DGAT1
sgRNA construct plasmid (1 mg/mL), 7.2 mL PB-Hygromycin
plasmid (1 mg/mL), and 2.8 mL PB-Transposase plasmid
(1 mg/mL). Transfection was performed in a NEPA21 Elec-
troporator with settings as described previously.2 After
transfection, priming medium was used for 5 days before
replacement by normal hSI-EM and selection with
Hygromcyin B (100 mg/mL; Invitrogen, Carlsbad, CA). The
organoids were passaged 1:4 by mechanical disruption at
day 9. Single organoids were picked 16 days after trans-
fection, disrupted into single cells by trypsinization with
TripLE, and scaled up as clonal organoid cell lines. Several
clones per transfection were screened for DGAT1 protein
expression by Western blot (Supplementary Figure 6C).
Organoids transfected with sgRNA#2 achieved 10/12
DGAT1KO clones, whereas organoids transfected with
sgRNA#678 achieved 3/11 DGAT1KO clones. Finally, 3
DGAT1KO clones were further characterized by genotyping
(Data not shown). Clone DGAT1KO #2–11 showed a deletion
of 280 base pairs (bp) on both alleles (NG_034192.1;
13347–13627). Clone DGAT1KO #678–02 showed a deletion
of 83 bp on both alleles (NG_034192.1; 13487–13570).
Clone DGAT1KO #678–07 showed a deletion of 83 bp on one
allele (NG_034192.1; 13487–13570); the other allele has a
deletion of 14 bp (NG_034192.1; 13485–13499) and an
insertion of 1 bp (NG_034192.1; T between 13486–13487)
(Supplementary Figure 6B).
Reverse-Transcriptase Polymerase Chain
Reaction
Protein synthesis inhibitor puromycin in a concentration
of 20 mg/12 mL was added to patient 3 and control
fibroblast culture 4 hours before harvesting for total RNA
extraction. Total RNA was extracted using the Qiagen
RNAeasy mini kit (Qiagen, Hilden, Germany). RNA was
reverse transcribed into complementary DNA (cDNA) by a
standard protocol using M-MLV reverse transcriptase
(Promega, Madison, WI). cDNA was PCR-amplified using
GoTaq polymerase and buffer (Promega) in 35 cycles of 20
seconds at 95C, 30 seconds at 60C, and 30 seconds at
72C in addition to a 7-minute final extension. The ampli-
cons were cleaned using Microcon centrifugal filter for
agarose gel–excised PCR products, and subsequently
sequenced using forward (gtaaaacgacggccagtGTGGACCC
CATCCAGGTGG) and reverse (caggaaacagctatgacTGAGCCA
GATGAGGTGATTGG) primers and run on an agarose gel.
Quantitative Real-Time Polymerase Chain
Reaction
RNA was isolated from Caco-2 cells or organoids grown
in either EM or DM for 5 days using the RNeasy Mini kit
(Qiagen) or TRIzol LS Reagent (Invitrogen), respectively,
according to the manufacturer’s protocol. cDNA was syn-
thesized using the iScript cDNA synthesis kit (Bio-Rad,
Hercules, CA) and amplified using SYBR green supermix
(Bio-Rad) in a Light Cycler96 (Roche, Basel, Switzerland)
according to the manufacturer’s protocol. The comparative
Ct method was used to quantify the data. The relative
quantity was defined as 2DDCt. In organoids and Caco-2
cells, HP1 and HPRT1 were used as housekeeper genes,
respectively. Sucrase-isomaltase (SI) and LGR5 were used to
determine the stem cell vs differentiation status of orga-
noids. Primers used were DGAT1-forward (FW): cgacgtgg-
gagccgc, DGAT1-reverse (RV): gctcaagatcagcatcacca,
HP1-FW: cccacgtcccaagatggat, HP1-RV: ctgatgcaccactcttctg-
gaa, SI-FW: ggacactggcttggagacaac, SI-RV: tccagcgggtacaga-
gatgat, LGR5-FW: gaatcccctgcccagtctc, LGR5-RV:
attgaaggcttcgcaaattct, HPRT1-FW: tgacactggcaaaacaatgca,
HPRT1-RV: ggtccttttcaccagcaagct.
Western Blotting
Caco-2 cells or organoids were lysed in Laemmli buffer
(0.12 mol/L Tris-HCl pH 6.8, 4% sodium dodecyl sulfate
[SDS], 20% glycerol, 0.05 mg/mL bromophenol blue, 35
mmol/L b-mercaptoethanol) and incubated at 100C for 5
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minutes. Fibroblasts were lysed in RIPA buffer (50 mM
HEPES, 150 mM NaCl, 10% glycerol, 1% Triton-X100, 2 mM
EDTA, 1% sodium deoxycholate, 50 mM NaF, 10 mM
NaO3V4) supplemented with protease inhibitor cocktail
(1:200, P8340; Sigma-Aldrich, St Louis, MO) then supple-
mented with Laemmli buffer. The protein concentration was
measured by performing a Lowry or Bradford protein assay.
Equal amounts of proteins were separated by SDS–
polyacrylamide gel electrophoresis, transferred to a poly-
vinylidene difluoride membrane (Merck Millipore, Billerica,
MA), blocked with 5% milk protein in TBST (0.3% Tween,
10 mM Tris-HCl pH 8, and 150 mM NaCl in H2O) and probed
with primary antibodies. The membranes were washed
with TBST and incubated with appropriate secondary anti-
bodies. Immunocomplexes were detected using the LI-COR
(Lincoln, NE) Odyssey. Caco-2 cells transfected with Flag-
DGAT1 c.629_631delCCT were left untreated or treated
with 2 mM MG132 (Cayman Chemicals, Ann Arbor, MI) for
16 hours.
The primary antibodies used were mouse anti-Flag M2
(1:3000; F3165; Sigma-Aldrich), rabbit anti-DGAT1 (1:1000;
ab181180; Abcam), rabbit anti-DGAT1 (1:1000, sc-32861;
Santa Cruz Biotechnology), rabbit anti-DGAT2 (1:1000, bs-
12998R; Bioss Antibodies, Woburn, MA), mouse anti-
GAPDH (1:3000, sc-32233; Santa Cruz Biotechnology),
anti-HA-HRP conjugate (1:3000, H6533; Sigma-Aldrich), and
rabbit anti-HSP90 (1:10000; kindly provided by Professor
L.J. Braakman). The secondary antibodies used were donkey
anti-mouse IgG IRDye 680 (1:10000; 926-32222; LI-COR)
and donkey anti-rabbit IgG IRDye 680RD (1:10000; 926-
68073; LI-COR), goat anti-mouse IgG-HRP (1:15000,
554002; BD Biosciences), and goat anti-rabbit IgG-HRP
(1:15000, 172-1019; Bio-Rad).
Lipid Droplet Assays
Oleic acid (OA) was conjugated to bovine serum albumin
(BSA) by heating the OA in phosphate-buffered saline (PBS)
to 70C for 1 hour. The OA suspension was then thoroughly
vortexed and slowly added to a solution of fatty acid–free
BSA in PBS kept at 37C in a molar ratio of OA:BSA (5:1)
to a final stock concentration of 10 mM OA and 2 mM BSA.
Thin Layer Chromatography
Folch extraction was performed by harvesting organoids,
washed in PBS and spun down, and the cell pellets were
frozen in ice-cold methanol on dry ice to stop cell meta-
bolism. Last, the cell pellets were homogenized using a
bullet blender, using glass bullets of 0.1-mm diameter for 2
minutes. Folch extraction was performed similar to the
original protocol.3 In short, chloroform and dH2O were
added to the cell lysate in methanol in a ratio of meth-
anol:chloroform:water (1:2:1). The mixture was vortexed
thoroughly, and incubated for 10 minutes in a shaking heat
block at 37C. Afterward, the lysates were spun down at
20,000 relative centrifugal force for 5 minutes to achieve a
phase separation. The bottom phase (chloroform/methanol)
was carefully collected and evaporated at 40C under flow of
nitrogen. The residual fatty precipitate was dissolved in
chloroform:methanol (2:1) and collected in glass vials.
Ubiquitin Pulldown Assay
Caco-2 cells were grown in 10-cm dishes and co-
transfected with 3 mg pcDNA3, Flag-DGAT1 WT, or Flag-
DGAT1 c.629_631delCCT and 3 mg His-ubiquitin. MG132
(2 mM) was added 32 hours posttransfection and the cells
were incubated at 37C for 16 hours. After incubation with
His-ubiquitin, transfected cells were once washed with PBS
and lysed in lysis buffer pH 8.0 containing 8 M urea (GE
Healthcare, Little Chalfont, UK), 7 mM NaH2PO4 (Merck,
Whitehouse Station, NJ), 100 mM Na2HPO4 (Merck), 10 mM
Tris-HCl pH 8.0 (Roche), 0.2% Triton-X100 (Sigma-Aldrich),
10 mM imidazole (Sigma-Aldrich), and 5 mM N-ethyl-
maleimide (Sigma-Aldrich); 10 mM b-mercaptoethanol
(Sigma-Aldrich) and Ni-NTA agarose beads (Qiagen) were
added and the cells were tumbled for 2 hours at room
temperature. The beads were washed twice in buffer pH 8.0,
2 times in buffer pH 6.3 (12 mM urea, 100 mM NaH2PO4, 30
mM Na2HPO4, 15 mM Tris-HCl pH 6.3, 0.3% Triton X-100,
30 mM imidazole), and once in wash buffer (100 mM NaCl
[Sigma-Aldrich], 20% glycerol [Sigma-Aldrich], 20 mM
Tris-HCl pH 8.0, 2 mM dithiothreitol [GE Healthcare] and 10
mM imidazole). Sample buffer (0.12 M Tris-HCl pH 6.8, 4%
SDS, 20% glycerol, 0.05 mg/mL bromophenol blue and
35 mM b-mercaptoethanol) was added. The samples
were incubated at 100C for 5 minutes and subjected to
Western blot.
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Supplementary
Figure 1. Histologic and
endoscopic characteris-
tics of intestines of
DGAT1-deficient patients.
(A) Colonoscopy (left) and
electron microscopy (EM,
right) revealed normal
intestinal structures in pa-
tient 1. (B) Periodic acid-
Schiff and EM of patient 7
were obtained during fat-
free diet and do not show
abnormalities. (C) Patient
10 shows cytosolic CD10
staining and lateral micro-
villi on EM.
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Supplementary Figure 2. Hematoxylin-eosin (H&E) and immunohistochemical staining for DGAT1 in (A) healthy controls, (B)
patient 2, and (C) patient 1.
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Supplementary
Figure 3. Family pedigrees
and Sanger sequencing
histograms of DGAT1 defi-
ciency. Filled shapes indi-
cate affected individuals,
half-filled are heterozygous
for mutation indicated, and
empty shapes indicate wild
type.
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Patient 3 Control
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Control
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Patient 3
Supplementary Figure 4. Defective mRNA splicing in patient
3. (A) Gel showing aberrant DGAT1 transcripts in mRNA
isolated from patient 3 fibroblasts with and without a 4-hour
puromycin treatment. * denotes aberrant transcript. ACTB
was used as control.
Supplementary Figure 5. DGAT1 c.629_631delCCT results in increased proteasomal degradation of DGAT1. Caco-2 cells
were stably transfected with indicated constructs. (A) qRT-PCR analysis of DGAT1 mRNA expression, relative to HPRT1, in
Caco-2 cells stably transfected with indicated constructs. Average and standard deviation of 3 independent experiments are
shown. (B) Transfected Caco-2 cells were untreated or treated with 2 mM MG132 for 16 hours. Protein expression was
determined by Western blot analysis using anti-Flag and anti-HSP90 antibodies. Results are representative of 3 independent
experiments. (C) Caco-2 cells were transiently transfected with His-ubiquitin and indicated constructs and treated with 2 mM
MG132 for 16 hours. Ubiquitination of DGAT1 was determined by a His pulldown and subsequent Western blot analysis using
anti-Flag antibodies. Results are representative of 3 independent experiments.
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Supplementary
Figure 6.Generation of
DGAT1 knockouts in
healthy human intestinal
organoids. (A) Targeting
strategy for the generation
of DGAT1 knockout orga-
noids using CRISPR/Cas9
genome editing. (B) Sche-
matic view of insertion-
deletion mutations of 3
DGAT1KO clones. Gray
areas represent deleted
sequences from the WT
DGAT1 gene. (C) Western
blot analysis of DGAT1
expression in DGAT1KO
organoids compared with
healthy control 1 (HC1)
and patient 8 (P8). Actin,
loading control.
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Supplementary Figure 7. Lipid droplet staining in Epstein-
Barr virus–derived B-lymphoblastic cell line (EBV B-LCL) of
patient 4 with and without OA. (A) Mean SSC-A and (B) Nile
Red mean fluorescence intensity (MFI) staining of lipid droplet
stained EBV B-LCLs.
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Supplementary Table 1.Genetic Description of DGAT1-deficient Patients in This Study and in Previous Reports
Patient Position Chr. 8 Reference Alternate DGAT1 mutation
DGAT1 mutated
protein
CADD
score
1 145540731 C T c.1202G>A p.W401X 38
2 145540731 C T c.1202G>A p.W401X 38
3 145542123 CCT CAGATGGGCAGGG
TGGGATGGG
c.573_574delAGinsCCCATCCC
ACCCTGCCCATCT
- 25.7
4 145541252 C T c. 937-1G>A - 24.9
5 145541233 T TG c.953insC p. I319Hfs *31 35
6 145541233 T TG c.953insC p. I319Hfs *31 35
7 145541968 TAGG T c.629_631delCCT p.S210_Y211delinsY 18.9
8 145541968 TAGG T c.629_631delCCT p.S210_Y211delinsY 18.9
9 145541968 TAGG T c.629_631delCCT p.S210_Y211delinsY 18.9
10 145541968 TAGG T c.629_631delCCT p.S210_Y211delinsY 18.9
Haas et al. 145541756 A G c.751þ2T>C p.A226_R250del 22.9
Stephen et al. (Fam 1) 145541756 A G c.751þ2T>C p.A226_R250del 22.9
Stephen et al. (Fam 2) 145541457 A G c.884T>C p.L295P 31
Gluchowski et al. 145542706 A G c.314T>C p.L105P 29.3
Ratchford et al. 145541074 TAGA T c.1013_1015delTCT p.F338del 22.3
145540567 C G c.1260C>G p.S420R 31
CADD, combined annotation dependent depletion; Chr, chromosome.
Supplementary Table 2.Serum Lipid Values of DGAT1-deficient Patients in This Study
Patient Age on test date Triglyceride (mg/dL) HDL (mg/dL) LDL (mg/dL) VLDL (mg/dL) Cholesterol (mg/dL)
1 5 mo 135 (<150) 25a (40–60) 12 (<110) 27 (<30) 63 (<170)
2 5 mo 84 (<150) 16a (40–60) 28 (<110) 16 (<30) 62 (<170)
3 11 mo 370a (<200) 9.5a (40–60) 23 (<110) ND 96 (<170)
4 8 y 123 (<180) Normal 110a (<110) ND 181a (<170)
5 ND ND ND ND ND ND
6 2 y 184 (<200) 21a (40–60) 13 (<110) 36a (<30) 59 (<170)
7 9 y 142 (<180) 32a (40–60) ND ND 139 (<170)
8 12 y 88 (<180) 30a (40–60) ND ND 112 (<170)
9 22 mo 124 (<180) 24a (40–60) ND Normal 139 (<170)
10 20 mo 165 (<180) ND ND ND 128 (<170)
NOTE. Parentheses indicate normal values.
HDL, high-density lipoprotein; LDL, low-density lipoprotein; ND, not determined; VLDL, very low-density lipoprotein.
aIndicates abnormal value
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Supplementary Table 3.Compilation of Clinical Characteristics and Specific Treatment of DGAT1-deficient Patients in This Study
Patient ID P1 P2 P3 P4 P5 P6 P7 P8 P9 P10
Recurrent infections Yes Yes No No No Yes No No Yes Yes
Type of infections Upper respiratory
tract
infections
NA Central line–related
fungal infection
NA NA Upper respiratory
infections,
recurrent
otitis media
NA NA (1) Sepsis:
Klebsiella and
Streptococcus
(2) Sepsis:
Escherichia coli
(1) NA
(2) Sepsis:
Klebsiella
(3) Sepsis:
Bacillus
cereus
(4) Sepsis:
Staphylococcus
aureus
Treatment for
infectious episodes
Antibiotics IV
or PO
NA Amphotericin B IV NA Prophylactic
immunoglobulins IV
Antibiotics PO NA NA Antibiotics IV Antibiotics IV
Response to treatment
for recurrent
infection
Well responded NA NA NA Well responded Well responded NA NA Well responded Well responded
Signs of liver disease NA NA NA Elevated
liver enzymes
Jaundice and
hepatomegaly.
Elevated liver enzymes.
Liver biopsy:
hepatocanalicular
and ductular
cholestasis,
paucity of
bile ducts,
mixed type;
hepatosteatosis
(10%), porto-portal
fibrosis and fibrotic
activity of 3/6.
Elevated liver
enzymes
NA NA Elevated liver
enzymes and
jaundice.
Toxic liver injury
due to effects of
long-term
treatment
with antifungal
drugs
(confirmed by
liver biopsy).
Elevated liver
enzymes
and jaundice.
Liver biopsy
normal.
Fecal elastase 1 levels
(normal range:
> 500 mg/g)
ND NA ND NA 130 mg/g ND NA NA >500 mg/g >500 mg/g
Serum albumin level
before
treatment (normal
range: >3.2 g/dL)
1.8 g/dL 1.8 g/dL 2.2 g/dL 2.8 g/dL 2.2 g/dL 2.59 g/dL NA 4.35 g/dL 2.38 g/dL 3.2 g/dL
Fecal-alpha-1-antitrypsin
level
(normal range: <5 mg/g)
NA ND Low ND NA NA NA NA 9.1 mg/g 7.6 mg/g
Specific treatment Fat-free formula
and medium
chain
triglyceride
Albumin IV
Albumin IV Albumin IV, TPN
Fat-free formula and
supplementation
of medium chain
triglyceride
Cholestyramine Creon hydrolyzed
formula
Creon Monthly infusion of
Intralipid and
Omegaven
supplementation
of lipid-soluble
vitamins
Monthly infusion
of Intralipid and
Omegaven
supplementation
of lipid-soluble
vitamins
TPN and small
bowel
transplantation
TPN and fat-free
formula
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Supplementary Table 3.Continued
Patient ID P1 P2 P3 P4 P5 P6 P7 P8 P9 P10
Clinical course after
treatment
Significant
improvement
Deceased Significant
improvement of
diarrhea
Significant
improvement;
diarrhea stopped
after treatment
Mild improvement.
His daily stool
frequency had
reduced with the
administrations
Creon, but his
weight and
height are
below 3rd
percentile.
No improvement of
failure to thrive,
but significant
improvement
of diarrhea.
After 2 years of age,
his symptoms
improved
spontaneously.
His weight is
now 16 kg
(3rd–10th
percentile),
height 104 cm
(3rd percentile)
Significant
improvement
Significant
improvement
Completely resolved
PLE. Tolerates
polymeric enteral
feeding.
Still stunted and
underweight by
causes secondary
to intestinal
transplantation
and several
autoimmune
problems.
NA
IV, intravenous; NA, not available; ND, not done; PLE, protein-losing enteropathy PO, per os; TPN, total parenteral nutrition.
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Supplementary Table 4.sgRNAs Used to Target DGAT1 for CRISPR/Cas9 Gene Editing
sgRNA ID Core sequence DNA Position DGAT1 gene Predicted cleavagea
sgRNA#2 GGCACCATGAGTTGACGTCG Exon 7 13621-13622 (AC)
sgRNA#6 TGTGCGCCATCAGCGCCAGC Exon 7 13570-13571 (TG)
sgRNA#7 GTGCGCCATCAGCGCCAGCA Exon 7 13569-13570 (CT)
sgRNA#8 GTGGCTGGCCCGAGACAGAT Intron 6–7 13486-13487 (CT)
sgRNA, single-guide RNA.
aAccording NCBI Reference Sequence: NG_034192.1; Homo sapiens diacylglycerol O-acyltransferase 1 (DGAT1).
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